Proshares Trust (ZBIO) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.
- Zenas BioPharma's Income towards Parent Company fell 3339.64% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 5006.66%. This contributed to the annual value of -$161.3 million for FY2024, which is 33461.64% down from last year.
- Per Zenas BioPharma's latest filing, its Income towards Parent Company stood at -$51.5 million for Q3 2025, which was down 3339.64% from -$52.2 million recorded in Q2 2025.
- In the past 5 years, Zenas BioPharma's Income towards Parent Company registered a high of $35.6 million during Q3 2023, and its lowest value of -$56.5 million during Q4 2024.
- Over the past 3 years, Zenas BioPharma's median Income towards Parent Company value was -$38.0 million (recorded in 2024), while the average stood at -$31.9 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 20837.08% in 2024, then tumbled by 2076.62% in 2025.
- Zenas BioPharma's Income towards Parent Company (Quarter) stood at -$24.8 million in 2023, then tumbled by 128.15% to -$56.5 million in 2024, then grew by 8.91% to -$51.5 million in 2025.
- Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.